Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orzel (UFT+Leucovorin) in metastatic breast cancer
NCT00005608Phase 2Terminated
- Sponsor
- Northwestern University
- Start
- Feb 2000
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur + uracil in breast cancer, sponsored by Northwestern University. Primary endpoint: Objective Response Rate. Started Feb 2000; status: terminated.
02
Drugs
tegafur + uracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005608.